ClinicalTrials.gg
CompletedNCT02004041Updated Jun 11, 2024Results posted

Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis

A Phase 2 interventional study of VLY-686 and Placebo in Treatment-resistant Pruritus Associated With Atopic Dermatitis, sponsored by Vanda Pharmaceuticals. Completed at 5 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-11.

Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 58 studies in Pruritus with a site in Germany — 5 open to participants now, 8 under way, 4 of them phase 3. Pruritus · Germany.

Enrollment
41st of 56
69 · median 153
Started
2013
with 1 other
Phase 2
17 of 58
1 open now
Registered
14th of 58
by date

Among the 58 studies in Pruritus with a site in Germany, this one is the 41st largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2013, is one of 17 in phase 2, and was the 14th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

5 of the 58 studies in Pruritus with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Pruritus with a site in Germany, or all of them as a file.
02

Study summary

This is randomized, double-blind, placebo-controlled study to test whether VLY-686 can reduce chronic pruritus in subjects with treatment-resistant pruritus associated with atopic dermatitis in comparison with placebo.

03

Conditions studied

  • Treatment-resistant Pruritus Associated With Atopic Dermatitis

Keywords

  • pruritus
  • atopic dermatitis
  • VLY-686
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ages 18 - 65 years, inclusive; suffering from atopic dermatitis with a SCORAD index at inclusion ≤80; with atopic lesions on arms, legs, trunk and neck;
  • Chronic pruritus with pruritus being actively present for at least 6 weeks prior to screening;
  • Males, non-fecund females, or females of using 2 independent highly effective barrier methods of when used correctly for a period of 35 days before the first dosing, during the study and for one month after the last dose and must have a negative pregnancy test at the screening and baseline visits.

Exclusion criteria

Exclusion Criteria:

  • Chronic pruritus due to conditions other than atopic dermatitis (AD) including the following conditions: Prurigo nodularis, Lichen simplex chronicus, Bullous pemphigoid;
  • Acute superinfection of AD.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    VLY-686

    Drug: VLY-686

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity.

    Responses were measured on a 100-mm Visual Analogue Scale (VAS), where the left end point was marked "no itch" (0 mm) and in the right end point was marked "worst imaginable itch" (100 mm).

    Time frame: 28 days

07

Results

Posted Jun 11, 2024

Participant flow

Participant flow — Overall Study
MilestoneVLY-686Placebo
Started3435
Completed3031
Not completed44

Outcome measures

PrimaryChange From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity.

Responses were measured on a 100-mm Visual Analogue Scale (VAS), where the left end point was marked "no itch" (0 mm) and in the right end point was marked "worst imaginable itch" (100 mm).

Time frame:
28 days
Reported as:
Least squares mean · mm
Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity.
mmVLY-686Placebo
Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity.-40.5 ± 5.30-36.5 ± 4.96

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent through study completion (approximately 63 days) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VLY-6860/34 (0%)0/34 (0%)12/34 (35.3%)
Placebo0/34 (0%)0/34 (0%)11/34 (32.4%)
Most frequent other events
Most frequent other events
EventVLY-686Placebo
FatigueGeneral disorders5/342/34
HeadacheNervous system disorders4/342/34
Dermatitis atopicSkin and subcutaneous tissue disorders4/341/34
NasopharyngitisRespiratory, thoracic and mediastinal disorders0/343/34
DiarrhoeaGastrointestinal disorders0/342/34
DizzinessNervous system disorders2/340/34
Skin burning sensationSkin and subcutaneous tissue disorders0/342/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)VLY-686PlaceboTotal
Mean36.6 ± 15.640.2 ± 14.538.4 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)VLY-686PlaceboTotal
Female192140
Male151429
Region of Enrollment
Region of Enrollment(participants)VLY-686PlaceboTotal
Germany343569
Pruritus 24 hours average intensity Visual Analogue Scale (VAS) at baseline
Pruritus 24 hours average intensity Visual Analogue Scale (VAS) at baseline(units on a scale)VLY-686PlaceboTotal
Mean76.1 ± 9.7477.2 ± 10.8776.6 ± 10.27
08

Study locations

5 sites
  • Vanda Investigational Site
    Dusseldorf, 40225, Germany
  • Vanda Investigational Site
    Hamburg, 22083, Germany
  • Vanda Investigational Site
    Jena, 07740, Germany
  • Vanda Investigational Site
    Kiel, 24105, Germany
  • Vanda Investigational Site
    Munster, 48147, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Feb 2015, 14 months.

Results were first posted in Jun 2024, 9 years 3 months after primary completion.

Of 37 industry-sponsored phase 2 interventional studies under Pruritus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 14 months is close to that.

Counting every sponsor, half of 52 studies reached it within 16 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2013
First posted
Dec 6, 2013
StartActual
Dec 10, 2013
Primary completionActual
Feb 19, 2015
CompletionActual
Feb 19, 2015
Results first posted
Jun 11, 2024
Last update
Jun 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02004041
Responsible party
Sponsor
First posted
Dec 6, 2013
Start date
Dec 10, 2013
Primary completion
Feb 19, 2015
Completion
Feb 19, 2015
Results posted
Jun 11, 2024
Last update
Jun 11, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion